File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A small molecule inhibitor of NF-κB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells

TitleA small molecule inhibitor of NF-κB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells
Authors
KeywordsAnti-invasion
Anti-proliferation
Apoptosis
DHMEQ
Nasopharyngeal carcinoma
NF-κB inhibitor
Issue Date2010
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canlet
Citation
Cancer Letters, 2010, v. 287 n. 1, p. 23-32 How to Cite?
AbstractDespite the demonstrated constitutive activation of NF-κB in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-κB, DHMEQ (which mainly blocks nuclear translocation of activated NF-κB) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G 2/M cell cycle arrest and apoptosis, and downregulation of NF-κB target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-κB targeting in NPC implicates the importance of targeting this pathway in NPC. © 2009 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/124480
ISSN
2023 Impact Factor: 9.1
2023 SCImago Journal Rankings: 2.595
ISI Accession Number ID
Funding AgencyGrant Number
Lee Hysan Foundation
United College, The Chinese University of Hong KongCA11117
CUHK
Funding Information:

This study was supported in part by Lee Hysan Foundation Research Grant and Endowment Fund Research Grant from United College, The Chinese University of Hong Kong (CA11117, awarded to VWYL) and a CUHK postdoctoral fellowship scheme (awarded to Y. Ho). Result of this study was presented in part at the Annual Meeting of AACR, 2008. We are grateful to Dr. Cesar Wong for his provision of NPC cell lines and our colleagues for their helpful assistance and advice.

References

 

DC FieldValueLanguage
dc.contributor.authorWong, JHTen_HK
dc.contributor.authorLui, VWYen_HK
dc.contributor.authorUmezawa, Ken_HK
dc.contributor.authorHo, Yen_HK
dc.contributor.authorWong, EYLen_HK
dc.contributor.authorNg, MHLen_HK
dc.contributor.authorCheng, SHen_HK
dc.contributor.authorTsang, CMen_HK
dc.contributor.authorTsao, SWen_HK
dc.contributor.authorChan, ATCen_HK
dc.date.accessioned2010-10-31T10:36:46Z-
dc.date.available2010-10-31T10:36:46Z-
dc.date.issued2010en_HK
dc.identifier.citationCancer Letters, 2010, v. 287 n. 1, p. 23-32en_HK
dc.identifier.issn0304-3835en_HK
dc.identifier.urihttp://hdl.handle.net/10722/124480-
dc.description.abstractDespite the demonstrated constitutive activation of NF-κB in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-κB, DHMEQ (which mainly blocks nuclear translocation of activated NF-κB) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G 2/M cell cycle arrest and apoptosis, and downregulation of NF-κB target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-κB targeting in NPC implicates the importance of targeting this pathway in NPC. © 2009 Elsevier Ireland Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/canleten_HK
dc.relation.ispartofCancer Lettersen_HK
dc.subjectAnti-invasionen_HK
dc.subjectAnti-proliferationen_HK
dc.subjectApoptosisen_HK
dc.subjectDHMEQen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectNF-κB inhibitoren_HK
dc.subject.meshApoptosis - drug effects-
dc.subject.meshBenzamides - pharmacology-
dc.subject.meshCyclohexanones - pharmacology-
dc.subject.meshNF-kappa B - antagonists and inhibitors-
dc.subject.meshNasopharyngeal Neoplasms - drug therapy - pathology-
dc.titleA small molecule inhibitor of NF-κB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cellsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0304-3835&volume=287&issue=1&spage=23&epage=32&date=2010&atitle=A+small+molecule+inhibitor+of+NF-kappaB,+dehydroxymethylepoxyquinomicin+(DHMEQ),+suppresses+growth+and+invasion+of+nasopharyngeal+carcinoma+(NPC)+cellsen_HK
dc.identifier.emailTsao, SW:gswtsao@hkucc.hku.hken_HK
dc.identifier.authorityTsao, SW=rp00399en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.canlet.2009.05.022en_HK
dc.identifier.pmid19560263-
dc.identifier.scopuseid_2-s2.0-72149129447en_HK
dc.identifier.hkuros182761en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-72149129447&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume287en_HK
dc.identifier.issue1en_HK
dc.identifier.spage23en_HK
dc.identifier.epage32en_HK
dc.identifier.isiWOS:000273897900003-
dc.publisher.placeIrelanden_HK
dc.identifier.scopusauthoridWong, JHT=35742294400en_HK
dc.identifier.scopusauthoridLui, VWY=7004231347en_HK
dc.identifier.scopusauthoridUmezawa, K=7103009158en_HK
dc.identifier.scopusauthoridHo, Y=26654872400en_HK
dc.identifier.scopusauthoridWong, EYL=8234468400en_HK
dc.identifier.scopusauthoridNg, MHL=35292609300en_HK
dc.identifier.scopusauthoridCheng, SH=7404681588en_HK
dc.identifier.scopusauthoridTsang, CM=24831236400en_HK
dc.identifier.scopusauthoridTsao, SW=7102813116en_HK
dc.identifier.scopusauthoridChan, ATC=13404833700en_HK
dc.identifier.citeulike5315442-
dc.identifier.issnl0304-3835-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats